Related references
Note: Only part of the references are listed.
Article
Cell Biology
Jing Hu et al.
Summary: This study revealed the essential roles and molecular mechanisms of HAGLR-mediated 5-Fu resistance in gastric cancer. By modulating miR-338-3p and glucose metabolism, HAGLR promotes chemoresistance in GC.
CELL BIOLOGY INTERNATIONAL
(2022)
Article
Genetics & Heredity
Qian Wang et al.
Summary: This study aimed to develop a prognostic signature for gastric cancer (GC) based on the tumor microenvironment (TME). By analyzing differentially expressed genes (DEGs) and performing regression analysis, a three-gene prognostic signature was identified and validated in multiple independent sets. The study also evaluated the immune characteristics between high-risk and low-risk patients to reveal potential immune mechanisms.
FRONTIERS IN GENETICS
(2022)
Review
Oncology
Mary Raina Angeli Fujiyoshi et al.
Summary: With advancements in endoscopic technologies, various classifications for early gastric cancer based on different endoscopic diagnostic modalities have been developed. This review provides an overview of these classifications and introduces novel classifications specifically designed for assessing and diagnosing gastric lesions.
Article
Oncology
Ming Xu et al.
Summary: This study developed a DAMPs gene signature to classify TNBC patients and predict their prognosis and immunotherapy outcome. An inflammatory DAMPs subtype was associated with the most favorable survival, while a DAMPs-suppressed subtype had the worst prognosis. The DAMPs subtyping system was validated in the TCGA cohort and showed potential for predicting immunotherapy efficacy.
FRONTIERS IN ONCOLOGY
(2022)
Article
Cell Biology
Yiyuan Zhang et al.
Summary: In this study, we investigated the different cell death signals in esophageal squamous cell carcinoma (ESCC) tumors and integrated that information to classify patients into different immunogenic cell death (ICD) subtypes. We found that the signals of necroptosis, pyroptosis, and ferroptosis were positively associated with activated immunity in ESCC. By analyzing transcriptomes and proteomic profiles, we identified two ICD subtypes that were correlated with better progression-free survival and overall survival. Cell fraction deconvolution analysis revealed more infiltrated leukocytes, especially antigen-presenting cells, in the ICD-high subtype. Additionally, we developed a 14-gene signature that can simplify subtyping and serve as a promising biomarker. Overall, this study successfully constructed an ICD scheme for predicting prognosis and immunotherapy efficacy in ESCC patients, revealing the important interplay between cell death signals and immune status.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Genetics & Heredity
Zehua Fan et al.
Summary: This study analyzed the subtypes and characteristics of stomach adenocarcinoma (STAD) by analyzing hypoxia pathway-related lncRNAs. The results identified three hypoxia lncRNA-related molecular subtypes characterized by different prognostic and immune conditions. The findings may provide a theoretical basis to improve the clinical diagnosis and treatment of STAD.
FUNCTIONAL & INTEGRATIVE GENOMICS
(2022)
Article
Pharmacology & Pharmacy
Dayong Ding et al.
Summary: By studying the relationship between long non-coding RNAs (lncRNAs) and immunogenic cell death (ICD), this study identified lncRNAs with prognostic value for stomach adenocarcinoma (STAD) patients. Using these lncRNAs, the authors developed a new risk model that can predict the cumulative overall survival rate of STAD patients and guide their individualized treatment.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Immunology
Songshan Feng et al.
Summary: Immunogenic cell death (ICD) is an important factor in tumor progression and therapeutic response. This study identifies ICD-related genes and constructs a risk signature that can predict prognosis and response to immune checkpoint blockade (ICB) treatment in glioblastoma (GBM) patients.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Genetics & Heredity
Xinghe Liao et al.
Summary: This study investigates the role of immunogenic cell death (ICD) in modifying the tumor immune microenvironment and develops a novel ICD-associated prognostic model for predicting the survival of patients with breast invasive carcinomas (BRCA).
FRONTIERS IN GENETICS
(2022)
Article
Genetics & Heredity
Mingjie Yuan et al.
Summary: This study identified and validated platelet activation-related lncRNAs as potential biomarkers for prognosis and immunotherapy in gastric cancer patients. The model established using seven PLT-related lncRNAs showed accuracy in predicting prognosis and was associated with response to immunotherapy. Patients with high-risk scores exhibited poorer prognosis and low immune cell infiltration, highlighting the potential therapeutic targets for GC patients.
FRONTIERS IN GENETICS
(2022)
Article
Genetics & Heredity
Cheng Zeng et al.
Summary: A prognostic signature consisting of 15 cellular senescence-related lncRNAs was identified, which could predict survival outcomes for stomach adenocarcinoma patients. Patients in the low-risk group may be more sensitive to immunotherapy.
FRONTIERS IN GENETICS
(2022)
Article
Oncology
Jin-Yong Zhou et al.
Summary: This study found that LINC01526 promotes gastric cancer progression by interacting with TARBP2 and degrading GNG7 mRNA. The study not only explores the role of LINC01526 in gastric cancer, but also provides a laboratory basis for its use as a new biomarker for diagnosis and therapeutic targets.
Article
Oncology
Xingxing Gao et al.
Summary: The combination of disulfiram and copper demonstrates anti-tumor effects in hepatocellular carcinoma by inducing immunogenic cell death and enhancing the efficacy of immune checkpoint blockade.
Article
Immunology
Mingang He et al.
Summary: This study developed a prognostic model for predicting hepatocellular carcinoma (HCC) outcomes by combining immunogenic cell death (ICD), immunity, and long non-coding RNA biomarkers. Different molecular subtypes and risk groups showed significant differences in response to chemotherapy drugs.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Junyang Wang et al.
Summary: Malignant tumors, such as gastric cancer, have the ability to evade the immune system by altering tumor-associated antigens, antigen presentation mechanisms, and the tumor microenvironment.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Jianmin Zeng et al.
Summary: This study aimed to construct a glycolysis-related lncRNA signature for predicting the prognosis of gastric cancer patients. Through various statistical analysis methods, we developed a prognostic signature consisting of 9 glycolysis-related lncRNAs, which could effectively predict the survival rates of gastric cancer patients. Furthermore, we found that high-risk patients were more likely to respond to immunotherapy, and the signature was associated with calcium signaling pathway, extracellular matrix receptor interaction, and focal adhesion.
PATHOLOGY & ONCOLOGY RESEARCH
(2022)
Article
Oncology
Yajun Han et al.
Summary: This study addresses the variation and low response rate to immunotherapy in melanoma patients by inducing immunogenic cell death (ICD). By constructing an ICD-based prognostic model, it was found that patients with high ICD expression showed longer overall survival and were associated with cell death and immune-related pathways. Additionally, the ICD risk characteristics were found to have predictive value for immunotherapy efficacy.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Chen Han et al.
Summary: This study constructed a prognostic signature of angiogenesis-related lncRNAs for accurately predicting the survival time of stomach adenocarcinoma (STAD) patients. The prognostic signature showed high efficacy and independence in predicting the prognosis of STAD patients. Additionally, the study also explored the coexpression of ARLncs with mRNAs, biological processes involved, and the correlation with angiogenesis markers, providing potential biomarkers and therapeutic strategies for STAD patients.
Review
Oncology
Kyriaki Tzogani et al.
Summary: The monoclonal antibody-drug conjugate belantamab mafodotin was approved in the European Union for the treatment of refractory/relapsed multiple myeloma, demonstrating durable response in highly pretreated patients with refractory disease. With a mechanism of action different from other authorized treatments, it presents a positive benefit-risk profile for this group of patients.
Article
Oncology
Hyuna Sung et al.
Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.
CA-A CANCER JOURNAL FOR CLINICIANS
(2021)
Article
Immunology
Shengchao Xu et al.
Summary: This study identified 340 HRLs and constructed a novel risk signature composed of 19 HRLs, which could predict the prognosis and immunotherapy response of LGG patients. The high-risk group showed low tumor purity and high immune infiltration.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Xinwen Wang et al.
Summary: By identifying ICD-associated subtypes, a new classification system based on ICD signatures can be established in HNSCC patients, which helps in assessing prognosis and effectiveness of immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Yu Zhang et al.
Summary: Combining apatinib with PD-L1 blockade treatment synergistically enhances antitumor immune responses and promotes HEV formation in GC, leading to delayed tumor growth, increased survival, improved prognosis, and changes in immune cell infiltration.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Article
Oncology
YaLing Li et al.
Summary: The study identified the long noncoding RNA BASP1-AS1 as crucial for the development and prognosis of melanoma. A four-gene prognostic model was constructed and BASP1-AS1 was found to promote cell proliferation, migration, and invasion in melanoma cells. Additionally, BASP1-AS1 was shown to interact with YBX1 and regulate the Notch signaling pathway, contributing to melanoma progression.
Review
Cell Biology
Sadegh Fattahi et al.
JOURNAL OF CELLULAR PHYSIOLOGY
(2020)
Article
Oncology
Min Liu et al.
TRANSLATIONAL CANCER RESEARCH
(2020)
Article
Pharmacology & Pharmacy
Anthony Markham
Article
Biotechnology & Applied Microbiology
Weixuan Sun et al.
ONCOTARGETS AND THERAPY
(2020)
Review
Cell Biology
Jingyi Zhou et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
(2019)
Review
Pathology
Ju Zou et al.
PATHOLOGY RESEARCH AND PRACTICE
(2019)
Review
Multidisciplinary Sciences
Robert D. Schreiber et al.
Article
Multidisciplinary Sciences
David A. Barbie et al.
Article
Multidisciplinary Sciences
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2005)
